Argenx Clinical Trial on Post-COVID POTS

The episode discusses a clinical trial conducted by Argenx on the medication efgartigimod, which could be a promising treatment for post-COVID POTS by depleting autoantibodies thought to contribute to the syndrome's symptoms. Dr. Artur Fedorowski and Dr. Joost Van Middendorp explore the trial's structure and objectives, aiming to assess the medication's safety and efficacy in improving POTS symptoms, such as autonomic disturbance. Eligible participants are adults diagnosed with POTS following a PCR-confirmed COVID-19 infection. Various symptomatic assessments and biomarkers will be used to evaluate changes post-treatment. While the trial focuses on post-COVID cases initially, there is hope its findings could extend to other POTS cases caused by different infections. However, widespread availability of a treatment is expected to take several years, pending successful trial outcomes and larger phase studies.